IL1B and myeloid sarcoma: Treatment with IFNβ in MS has been linked to the inhibition of cell migration [18], down-regulation of cell activation [19], [20], improvement of blood brain barrier (BBB) function [21] and regulation of pro and anti-inflammatory cytokine balance, including IL-1β [22], [23].